［1］Hattinger CM，Michelacci F，Sella F，et al．Excision repair cross-complementation group 1 protein expression predicts survival in patients with high grade non-metastatic osteosarcoma treated with neoadjuvant chemotherapy［J］． Histopathology，2015，67(3)：338-347.
［2］ Hansen AR，Hughes BG，Paul S，et al．Single institution retrospective review of perioperative chemotherapy in adult and adolescent patients with operable osteosarcoma［J］．Asia Pac J Clin Oncol，2016，12(2)：e222-e228.
［3］ BAI RJ，CHENG XG，GU X，et al.X-ray CT and MRI findings of long bone shaft osteosarcoma［J］.Chin J Radiol,2011,45(1)：60-64.［白荣杰,程晓光,顾翔,等.长骨骨干骨肉瘤 X 线、CT及 MRI 表现［J］.中华放射学杂志,2011,45(1)：60-64.］
［4］ NIU XH.The standardized diagnosis and treatment of osteosarcoma in China is imperative［J］．Chin J Oncol,2013,35(3)：161-163．［牛晓辉．中国骨肉瘤的规范化诊治势在必行［J］．中华肿瘤杂志,2013,35(3)：161-163．］
［5］ NIU XH，XU HR.Advances in chemotherapy for osteosarcoma［J］.China Oncology,2012,22(9)：663-664．［牛晓辉,徐海荣.骨肉瘤的化疗进展［J］.中国癌症杂志,2012,22(9)：663-664．］
［6］ CHEN J，LIU YX.Advances in chemotherapy for osteosarcoma［J］.Zhejiang Journal of Integrated Traditional Chinese and Western Medicine，2010，20(1)：53-55.［陈婧,刘云霞.骨肉瘤化疗研究进展［J］.浙江中西医结合杂志，2010，20(1)：53-55.］
［7］ He H，Ni J，Huang J．Molecular mechanisms of chemoresistance in osteosarcoma（Review）［J］．Oncol Lett，2014，7(5)：1352-1362．
［8］ XU J，HU YM，YANG YB，et al.Health measurement scale SF-36［J］.Chinese Journal of Behavioral Medical Science，1999，8(2)：150-152.［许军,胡敏燕,杨云滨,等.健康测量量表SF-36［J］.中国行为医学科学,1999，8(2)：150-152.］
［9］ Ferrari S，Meazza C，Palmerini E，et al． Nonmetastatic osteosarcoma of the extremity． Neoadjuvant chemotherapy with methotrexate，cisplatin，doxorubicin and ifosfamide． An Italian Sarcoma Group study（ISG/OS-Oss) ［J］．Tumori，2014，100(6)：612-619.
［10］ CHENG DL，LIU GH.Advances in the treatment of osteosarcoma［J］.Orthopedic Journal of China，2009，17(15)：1158-1160.［成德亮,刘国辉.骨肉瘤治疗的研究进展［J］.中国矫形外科杂志，2009，17(15)：1158-1160.］
［11］ CHI XF，JIANG H，YANG D.The role of ID3 gene in reversing cisplatin resistance in osteosarcoma and its mechanism［J］.Oncology Progress,2018,16(2):167-170,182.［池晓峰,姜宏,杨东.ID3基因在逆转骨肉瘤顺铂耐药中的作用及其机制的研究［J］.癌症进展,2018,16(2):167-170,182.］
［12］ LU KY，ZHU X，HU Y，et al.Relationship between cisplatin resistance and FoxM1 Rad50 in osteosarcoma and its clinical significance［J］.Chinese Journal of Clinical and Experimental Pathology,2018,34(4):413-418.［鲁康洋,朱霞,胡勇,等.骨肉瘤顺铂化疗耐药与FoxM1、Rad50的关系及临床意义［J］.临床与实验病理学杂志,2018,34(4):413-418.］
［13］ WANG Yunmei，LIU Shuguang，WEI Xiaohui，et al.Efficacy of second-line chemotherapy for advanced osteosarcoma［J］.Modern Oncology,2018,26(07):1103-1105.［王云梅,刘曙光,魏晓辉,等.晚期骨肉瘤的二线化疗疗效观察［J］.现代肿瘤医学,2018,26(07):1103-1105.］
［14］ Park HJ，Bae JS，Kim KM，et al.The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin inosteosarcoma［J］.J Exp Clin Cancer Res,2018,37(1):107.
［15］ WANG J，LV Z.Effect of liposomal-mediated system TK/GCV combined with dol on in vitro cytotoxicity of osteosarcoma cells［J］.National Medical Frontiers of China,2011,6(23):9-11.［王军,吕智.脂质体介导的TK/GCV系统联合多柔比星对骨肉瘤细胞体外杀伤作用研究［J］.中国医疗前沿,2011,6(23):9-11.］
［16］ Haghiralsadat F，Amoabediny G，Sheikhha MH，et al.A novel approach on drug delivery:Investigation of A new nano-formulation of liposomal doxorubicin and biological evaluation of entrapped doxorubicin on various osteosarcoma cell lines［J］.Cell J,2017,19(Suppl 1):55-65.
［17］ LIU X，ZHANG XW，WANG HJ，et al.Polyethylene glycol liposome and isophosphamide in the treatment of advanced metastatic soft tissue sarcoma［J］.China Oncology,2017,27(09):687-692.［刘欣,张晓伟,王惠杰,等.聚乙二醇化脂质体多柔比星联合异环磷酰胺治疗晚期转移性软组织肉瘤［J］.中国癌症杂志,2017,27(09):687-692.］
［18］ Gaspar N，Occean BV，Pacquement H，et al.Results of methotrexate-etoposide-ifosfamide based regimen（M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study［J］.Eur J Cancer,2018(88):57-66.
［19］ CHEN F，GUO Z，QU R.Clinical study on treatment of osteosarcoma with high dose of isophosphamide combined with liposomal adriamycin［J］.The Practical Journal of Cancer,2015,30(05):676-678.［陈丰,郭智,瞿嵘.大剂量异环磷酰胺联合脂质体阿霉素治疗骨肉瘤的临床研究［J］.实用癌症杂志,2015,30(05):676-678.］
［20］ Aznab M，Hematti M.Evaluation of clinical process in osteosarcoma patients treated with chemotherapy including cisplatin，adriamycin，ifosfamide，and etoposide and determination of the treatment sequels in a long-term 11-year follow-up［J］.J Cancer Res Ther,2017,13(2):291-296.
［21］ Fan XL，Cai GP，Zhu LL，et al.Efficacy and safety of ifosfamide-based chemotherapy for osteosarcoma:A Meta-analysis［J］.Drug Des Devel Ther,2015（9）:5925-5932.